Effects of captopril on contractility after myocardial infarction

Experimental observations

Sheldon E. Litwin, Thomas E. Raya, Alberta Warner, Christine M. Litwin, Steven Goldman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

After large myocardial infarction, compromised left ventricular (LV) function and changes in the peripheral circulation result in the syndrome of chronic congestive heart failure. Although treatment with angiotensin-converting enzyme inhibitors improve cardiovascular function, it is difficult to determine whether this benefit is due to changes in organ versus muscle function. The rat model of heart failure, created by ligating the left coronary artery, results in pathophysiology that is similar to that seen in patients, i.e., increased LV end-diastolic pressure and volume, hypertrophy of the noninfarcted myocardium, prolongation of the time constant of LV relaxation, decreased venous compliance, and increased total blood volume. In noninfarcted papillary muscles, isolated from rats with heart failure, maximal developed tension and peak rate of tension rise ( +dT dt) are decreased, time to peak tension is prolonged, and myocardial stiffness is increased. Morphologic changes include an increase in papillary muscle myocyte cross-sectional area and an increase in myocardial hydroxyproline content. Captopril (2 g/liter drinking water) alters LV loading by decreasing arterial pressure, increasing venous compliance, and decreasing blood volume. This results in a decrease in LV end-diastolic pressure and volume. In the noninfarcted myocardium, time to peak tension is shortened, whereas developed tension, +dT dt, and muscle stiffness remain abnormal. Captopril decreases myocyte cross-sectional area, but collagen content remains elevated. Thus, in the rat infarct model of heart failure, treatment with captopril alters LV remodeling and hypertrophy but produces only modest improvement in muscle function. In this model, after treatment for 3 weeks, it appears that the major benefit from angiotensin-converting enzyme inhibition is due to improvements in organ function resulting from changes in loading conditions, whereas muscle function remains compromised.

Original languageEnglish (US)
Pages (from-to)26-34
Number of pages9
JournalThe American journal of cardiology
Volume68
Issue number14
DOIs
StatePublished - Nov 18 1991

Fingerprint

Captopril
Heart Failure
Myocardial Infarction
Muscles
Papillary Muscles
Blood Volume
Stroke Volume
Muscle Cells
Compliance
Myocardium
Blood Pressure
Ventricular Remodeling
Hydroxyproline
Left Ventricular Hypertrophy
Peptidyl-Dipeptidase A
Left Ventricular Function
Angiotensin-Converting Enzyme Inhibitors
Drinking Water
Hypertrophy
Coronary Vessels

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effects of captopril on contractility after myocardial infarction : Experimental observations. / Litwin, Sheldon E.; Raya, Thomas E.; Warner, Alberta; Litwin, Christine M.; Goldman, Steven.

In: The American journal of cardiology, Vol. 68, No. 14, 18.11.1991, p. 26-34.

Research output: Contribution to journalArticle

Litwin, Sheldon E. ; Raya, Thomas E. ; Warner, Alberta ; Litwin, Christine M. ; Goldman, Steven. / Effects of captopril on contractility after myocardial infarction : Experimental observations. In: The American journal of cardiology. 1991 ; Vol. 68, No. 14. pp. 26-34.
@article{580282f49e324400876a5f62af7511e2,
title = "Effects of captopril on contractility after myocardial infarction: Experimental observations",
abstract = "After large myocardial infarction, compromised left ventricular (LV) function and changes in the peripheral circulation result in the syndrome of chronic congestive heart failure. Although treatment with angiotensin-converting enzyme inhibitors improve cardiovascular function, it is difficult to determine whether this benefit is due to changes in organ versus muscle function. The rat model of heart failure, created by ligating the left coronary artery, results in pathophysiology that is similar to that seen in patients, i.e., increased LV end-diastolic pressure and volume, hypertrophy of the noninfarcted myocardium, prolongation of the time constant of LV relaxation, decreased venous compliance, and increased total blood volume. In noninfarcted papillary muscles, isolated from rats with heart failure, maximal developed tension and peak rate of tension rise ( +dT dt) are decreased, time to peak tension is prolonged, and myocardial stiffness is increased. Morphologic changes include an increase in papillary muscle myocyte cross-sectional area and an increase in myocardial hydroxyproline content. Captopril (2 g/liter drinking water) alters LV loading by decreasing arterial pressure, increasing venous compliance, and decreasing blood volume. This results in a decrease in LV end-diastolic pressure and volume. In the noninfarcted myocardium, time to peak tension is shortened, whereas developed tension, +dT dt, and muscle stiffness remain abnormal. Captopril decreases myocyte cross-sectional area, but collagen content remains elevated. Thus, in the rat infarct model of heart failure, treatment with captopril alters LV remodeling and hypertrophy but produces only modest improvement in muscle function. In this model, after treatment for 3 weeks, it appears that the major benefit from angiotensin-converting enzyme inhibition is due to improvements in organ function resulting from changes in loading conditions, whereas muscle function remains compromised.",
author = "Litwin, {Sheldon E.} and Raya, {Thomas E.} and Alberta Warner and Litwin, {Christine M.} and Steven Goldman",
year = "1991",
month = "11",
day = "18",
doi = "10.1016/0002-9149(91)90258-M",
language = "English (US)",
volume = "68",
pages = "26--34",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "14",

}

TY - JOUR

T1 - Effects of captopril on contractility after myocardial infarction

T2 - Experimental observations

AU - Litwin, Sheldon E.

AU - Raya, Thomas E.

AU - Warner, Alberta

AU - Litwin, Christine M.

AU - Goldman, Steven

PY - 1991/11/18

Y1 - 1991/11/18

N2 - After large myocardial infarction, compromised left ventricular (LV) function and changes in the peripheral circulation result in the syndrome of chronic congestive heart failure. Although treatment with angiotensin-converting enzyme inhibitors improve cardiovascular function, it is difficult to determine whether this benefit is due to changes in organ versus muscle function. The rat model of heart failure, created by ligating the left coronary artery, results in pathophysiology that is similar to that seen in patients, i.e., increased LV end-diastolic pressure and volume, hypertrophy of the noninfarcted myocardium, prolongation of the time constant of LV relaxation, decreased venous compliance, and increased total blood volume. In noninfarcted papillary muscles, isolated from rats with heart failure, maximal developed tension and peak rate of tension rise ( +dT dt) are decreased, time to peak tension is prolonged, and myocardial stiffness is increased. Morphologic changes include an increase in papillary muscle myocyte cross-sectional area and an increase in myocardial hydroxyproline content. Captopril (2 g/liter drinking water) alters LV loading by decreasing arterial pressure, increasing venous compliance, and decreasing blood volume. This results in a decrease in LV end-diastolic pressure and volume. In the noninfarcted myocardium, time to peak tension is shortened, whereas developed tension, +dT dt, and muscle stiffness remain abnormal. Captopril decreases myocyte cross-sectional area, but collagen content remains elevated. Thus, in the rat infarct model of heart failure, treatment with captopril alters LV remodeling and hypertrophy but produces only modest improvement in muscle function. In this model, after treatment for 3 weeks, it appears that the major benefit from angiotensin-converting enzyme inhibition is due to improvements in organ function resulting from changes in loading conditions, whereas muscle function remains compromised.

AB - After large myocardial infarction, compromised left ventricular (LV) function and changes in the peripheral circulation result in the syndrome of chronic congestive heart failure. Although treatment with angiotensin-converting enzyme inhibitors improve cardiovascular function, it is difficult to determine whether this benefit is due to changes in organ versus muscle function. The rat model of heart failure, created by ligating the left coronary artery, results in pathophysiology that is similar to that seen in patients, i.e., increased LV end-diastolic pressure and volume, hypertrophy of the noninfarcted myocardium, prolongation of the time constant of LV relaxation, decreased venous compliance, and increased total blood volume. In noninfarcted papillary muscles, isolated from rats with heart failure, maximal developed tension and peak rate of tension rise ( +dT dt) are decreased, time to peak tension is prolonged, and myocardial stiffness is increased. Morphologic changes include an increase in papillary muscle myocyte cross-sectional area and an increase in myocardial hydroxyproline content. Captopril (2 g/liter drinking water) alters LV loading by decreasing arterial pressure, increasing venous compliance, and decreasing blood volume. This results in a decrease in LV end-diastolic pressure and volume. In the noninfarcted myocardium, time to peak tension is shortened, whereas developed tension, +dT dt, and muscle stiffness remain abnormal. Captopril decreases myocyte cross-sectional area, but collagen content remains elevated. Thus, in the rat infarct model of heart failure, treatment with captopril alters LV remodeling and hypertrophy but produces only modest improvement in muscle function. In this model, after treatment for 3 weeks, it appears that the major benefit from angiotensin-converting enzyme inhibition is due to improvements in organ function resulting from changes in loading conditions, whereas muscle function remains compromised.

UR - http://www.scopus.com/inward/record.url?scp=0026331894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026331894&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(91)90258-M

DO - 10.1016/0002-9149(91)90258-M

M3 - Article

VL - 68

SP - 26

EP - 34

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 14

ER -